Lithium Australia begins Mexican adventure

|

Published 19-APR-2016 16:45 P.M.

|

2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

Lithium Australia (ASX:LIT) has fired the starting gun on its Mexican adventure, with fieldwork at Sonora to begin immediately.

It told its investors earlier today that it, in joint venture with TSX-listed Alix Resources, had started work on what it hopes will become a valuable lithium clay project.

The project is along strike from the Sonora Project, which is being developed by Rare Earth Minerals and Bacanora Minerals with an eye toward supplying lithium-ion battery giant Tesla to the north.

The deal was a sign that end-users are increasingly becoming involved in the upstream exploration game, rather than waiting for material to appear on a spot market.

If the initial analysis is right, Alix’s permits contain a low-grade lithium clay, one LIT will be hoping to bring up to grade using its Sileach process.

Map of LIT's project in Mexico

Map of LIT’s project in Mexico

The Sileach process has been touted as a way to bring low-grade micas which contain graphite, and turn them into a lithium-oxide product in line with industry specifications.

LIT has the opportunity to earn in for a 65% stake as the project progresses, and now the starter’s gun has been fired investors will be waiting for first results from the project.

At this stage the plan is for samples the project will be brought to LIT for initial analysis, and should that hold potential LIT will produce a commercial development proposal, which will contain a roadmap for ultimate commercialisation using LIT’s methods.

Then the JV will move onto small-scale testing, and then ultimately commercial arrangements.

The terms of these potential arrangements will be written into the definitive joint venture agreement, but may be changed.

LIT has been increasingly busy building its upstream position of late, most recently earning into an exploration license in the Northern Territory which the company has compared to the largest hard-rock lithium mine in the world, Greenbushes.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X